Exploratory study of an anti-PD-L1/TGF-β antibody, TQB2858, in patients with refractory or recurrent osteosarcoma and alveolar soft part sarcoma: a report from Chinese sarcoma study group (TQB2858-Ib-02)

[1]  P. Zhang,et al.  Integrated analysis of single-cell and bulk RNA sequencing data reveals an immunostimulatory microenvironment in tumor thrombus of osteosarcoma , 2023, Oncogenesis.

[2]  Zhao Zhang,et al.  Comprehensive landscape of TGFβ-related signature in osteosarcoma for predicting prognosis, immune characteristics, and therapeutic response , 2023, Journal of bone oncology.

[3]  A. Maleddu,et al.  Much Ado About ASPS: The Rapidly Changing Treatment Paradigms of 2022. , 2023, Clinical Cancer Research.

[4]  Xiaojing Zhang,et al.  Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial , 2022, BMC Medicine.

[5]  J. E. Brewer,et al.  Engineering Cancer Antigen-Specific T Cells to Overcome the Immunosuppressive Effects of TGF-β , 2021, The Journal of Immunology.

[6]  P. Meltzer,et al.  New Horizons in the Treatment of Osteosarcoma. , 2021, The New England journal of medicine.

[7]  Z. Shao,et al.  Management of Apatinib-Related Adverse Events in Patients With Advanced Osteosarcoma From Four Prospective Trials: Chinese Sarcoma Study Group Experience , 2021, Frontiers in Oncology.

[8]  S. Rottey,et al.  Immune checkpoint inhibitors in treatment of soft-tissue sarcoma: A systematic review and meta-analysis. , 2021, European journal of cancer.

[9]  S. Lorenz,et al.  Pembrolizumab in advanced osteosarcoma: results of a single-arm, open-label, phase 2 trial , 2021, Cancer Immunology, Immunotherapy.

[10]  S. Menéndez,et al.  GARP promotes the proliferation and therapeutic resistance of bone sarcoma cancer cells through the activation of TGF-β , 2020, Cell Death & Disease.

[11]  D. Shen,et al.  Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial , 2020, Journal for ImmunoTherapy of Cancer.

[12]  D. Sher,et al.  TGF-beta: a master immune regulator , 2020, Expert opinion on therapeutic targets.

[13]  Rachel A. Kudgus,et al.  Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial. , 2020, The Lancet. Oncology.

[14]  P. A. Futreal,et al.  Immuno-genomic landscape of osteosarcoma , 2020, Nature Communications.

[15]  J. Schlom,et al.  Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances , 2020, Journal for ImmunoTherapy of Cancer.

[16]  L. Kennedy,et al.  A review of cancer immunotherapy toxicity , 2020, CA: a cancer journal for clinicians.

[17]  David M. Thomas,et al.  Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas , 2019, Modern Pathology.

[18]  R. Maki,et al.  Diagnosis, Prognosis, and Treatment of Alveolar Soft-Part Sarcoma: A Review , 2019, JAMA oncology.

[19]  J. Crowley,et al.  Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial. , 2017, The Lancet. Oncology.

[20]  Robert Ford,et al.  iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. , 2017, The Lancet. Oncology.

[21]  G. Blobe,et al.  Dichotomous roles of TGF-β in human cancer. , 2016, Biochemical Society transactions.

[22]  Michael W. Bishop,et al.  Future directions in the treatment of osteosarcoma , 2016, Current opinion in pediatrics.

[23]  J. Lebrun.  The Dual Role of TGFβ in Human Cancer: From Tumor Suppression to Cancer Metastasis , 2012, ISRN molecular biology.

[24]  A. Razak,et al.  Immunotherapy in soft-tissue sarcoma. , 2020, Current oncology.

[25]  F. Verrecchia,et al.  Transforming Growth Factor-β Signaling Plays a Pivotal Role in the Interplay Between Osteosarcoma Cells and Their Microenvironment , 2018, Front. Oncol..

[26]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[27]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..

[28]  C. Conill,et al.  Can Karnofsky performance status be transformed to the Eastern Cooperative Oncology Group scoring scale and vice versa? , 1992, European journal of cancer.